₩ 102700
Key Takeaways
Risk factor
Fair trading liquidity
Profitability factor
Greatly overvalued vs peers
About
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Target Price
The average target price of 326030.KS is 146049 and suggests 44% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
